Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 14, 2003. The report is a disclosure of changes in directors' interests in the company's Ordinary Shares and does not contain financial performance data for a fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding equity movements and does not include financial statements.
Material Changes
The filing details specific movements in shareholdings related to employee benefit plans:
- US Retirement Savings Plan: On November 13, 2003, the number of Ordinary Share ADRs held by the fund decreased from 18,860,128 to 18,786,047. The average price for this movement was $46.76.
- Employee Share Option Plan 1991: On November 12, 2003, the GSK Trust transferred a total of 39,254 Ordinary Shares (12,856 in one transaction and 26,398 in another) to plan participants.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future business performance. It notes that Directors Dr. J-P Garnier and Mr. J.D. Coombe are potentially interested in shares held within the discretionary trusts (the US Retirement Savings Plan and the GSK Trust) in the same manner as other employees and former employees.
Key Facts for Investor Verification
- Verify the impact of the ADR reduction in the US Retirement Savings Plan on overall director shareholding percentages.
- Confirm the total number of shares transferred to the SmithKline Beecham Employee Share Option Plan 1991 participants.
- Note that this filing does not reflect operational or financial results for the company.